Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Susan HalabiAkash RoyLarysa H M RydzewskaSiyuan GuoPeter J GodolphinMaha H A HussainCatherine M TangenIan ThompsonWanling XieMichael A CarducciMatthew R SmithMichael J MorrisGwenaëlle GravisDavid P DearnaleyPaul VerhagenTakayuki GotoNicholas D JamesMarc E BuyseJayne F TierneyChristopher J Sweeneynull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Both rPFS and cPFS appear to be promising surrogate end points for OS. The STE of 0.80 or higher makes it viable for either rPFS or cPFS to be used as the primary end point that is surrogate for OS in phase III mHSPC trials with testosterone suppression alone as the backbone therapy and would expedite trial conduct.